康缘品牌怎么样 申请店铺

我要投票 康缘在中草药行业中的票数:39 更新时间:2024-12-27
康缘是哪个国家的品牌?「康缘」是 江苏康缘药业股份有限公司 旗下著名品牌。该品牌发源于江苏,由创始人肖伟在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
康缘怎么样

充满活力的创新型制药企业--江苏康缘药业股份有限公司是一家集中药研发、生产、贸易为一体的大型中药企业,是国家中药现代化示范企业、国家重点高新技术企业、国内A股上市公司、国家创新型企业,全国制药工业百强企业,获国家“质量管理先进企业”,“守合同重信用企业”等荣誉称号,“康缘”商标为国家驰名商标。

公司坚持以科研创新为先导,不断提升企业自主创新实力。企业设立博士后科研工作站、江苏省院士工作站,成立康缘现代中药研究院,拥有一支包括6名博士后、12名博士、80余名硕士在内的180多名科研人员组成的研究队伍;先后与中国医学科学院药物研究所、中科院上海有机化学研究所、大连工业大学等科研院所联合建立了十余个共建实验室,并在美国建立了创新药物研发公司,自主创新能力位居国内同行前列,发明专利授权量在同行业中名列前茅。2002年康缘药业被批准设立博士后科研工作站,2005年公司研发中心被认定为国家级企业技术中心。2010年1月康缘研究院被国家科技部批准建设“中药制药过程新技术国家重点实验室”,进入我国中医药创新体系国家队行列。

康缘药业拥有国内最大的智能化中药材提取生产线,具有年处理生药材10000吨的能力;拥有通过国家GMP验证的制剂车间,配套完善的备料中心、质量检测中心、动力中心、智能管理中心,设有硬胶囊、软胶囊、小容量注射剂、冻干粉针剂等十三条最先进的生产线,具备年生产硬胶囊12亿粒、软胶囊3.4亿粒、口服液1亿支、小容量注射剂5亿支、冻干粉针剂600万支、片剂15亿片、颗粒剂1000吨的能力。

康缘药业全力推行专业化、学术化营销,建立了一支高素质、专业化1600余人的营销队伍,在全国29个省市建立了34个销售分公司、226多个中心办事处,与全国146家医药商业公司建立了长期稳定的业务关系,产品覆盖近7000家县级以上医疗单位。

Jiangsu Kangyuan Pharmaceutical Co., Ltd., a dynamic and innovative pharmaceutical enterprise, is a large-scale Chinese medicine enterprise integrating research and development, production and trade of traditional Chinese medicine. It is a national modern demonstration enterprise of traditional Chinese medicine, a national key high-tech enterprise, A-share listed company, a national innovative enterprise, and one of the top 100 pharmaceutical enterprises in China, It has won the honorary titles of "advanced quality management enterprise", "contract abiding and trustworthy enterprise" and "Kangyuan" trademark is a national well-known trademark. The company adheres to scientific research and innovation as the guide, and constantly improves the independent innovation strength of the enterprise. The company has set up postdoctoral research station, Jiangsu academician workstation, and Kangyuan modern Chinese Medicine Research Institute. It has a research team of more than 180 researchers, including 6 postdoctoral, 12 doctors, and more than 80 masters. It has been jointly built with the Institute of medicine of Chinese Academy of Medical Sciences, Shanghai Institute of organic chemistry of Chinese Academy of Sciences, Dalian University of technology and other research institutes More than ten co built laboratories have been set up, and innovative drug R & D companies have been established in the United States. The independent innovation ability ranks in the forefront of domestic peers, and the amount of invention patent authorization ranks first in the same industry. In 2002, Kangyuan pharmaceutical was approved to set up a postdoctoral research workstation, and in 2005, the company's R & D center was recognized as a national enterprise technology center. In January 2010, Kangyuan Research Institute was approved by the Ministry of science and technology of the people's Republic of China to build the "National Key Laboratory of new technology in the pharmaceutical process of traditional Chinese medicine", and entered the ranks of the national team of Chinese medicine innovation system. Kangyuan Pharmaceutical Co., Ltd. has the largest intelligent production line of Chinese herbal medicine extraction in China, with an annual capacity of 10000 tons of raw herbs. It has a preparation workshop certified by the national GMP, a complete set of material preparation center, quality inspection center, power center, intelligent management center, and 13 most advanced production lines, including hard capsule, soft capsule, small volume injection, freeze-dried powder injection, It has the annual production capacity of 1.2 billion hard capsules, 340 million soft capsules, 100 million oral liquids, 500 million small volume injections, 6 million lyophilized powder injections, 1.5 billion tablets and 1000 tons of granules. Kangyuan pharmaceutical industry has made great efforts to promote professional and academic marketing, established a high-quality and professional marketing team of more than 1600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, established long-term and stable business relations with 146 pharmaceutical commercial companies across the country, with products covering nearly 7000 medical units above the county level.

本文链接: https://brand.waitui.com/0310949a5.html 联系电话:400-828-5168

千城特选小程序码

7×24h 快讯

沪深两市成交额连续第63个交易日突破1万亿

36氪获悉,沪深两市成交额连续第63个交易日突破1万亿,较上日此时放量近1100亿。

28分钟前

日本政府通过温室气体减排新目标:2035年度较2013年度减排60%

据报道,日本政府12月27日召开全球变暖对策推进总部(总部长:首相石破茂)会议,通过了全球变暖对策计划的修改方案,其中提出“2035年度较2013年度减排60%、2040年度减排73%”的温室气体减排新目标。日本政府将在征求公众意见后,在内阁会议上敲定修改方案,并力争在2025年2月底前向联合国汇报。(界面)

28分钟前

南京公用宣布并购,股价“提前”涨停,公司最新回应

26日晚间,南京公用公告,公司拟购买宇谷科技约68%股权并募集配套资金。本次交易预计不构成重大资产重组,不构成重组上市。公司股票自12月27日开市起停牌,预计不超过10个交易日。公告当日,该股录得涨停。对此,南京公用相关人士表示,公司主营能源业务,以传统燃气为主。同时也在布局新能源领域,包括充电桩业务等,不过体量尚小。目前相关事宜处于初步商谈阶段,后续情况以公司公告为准。关于股价“提前”涨停,前述人士表示,公司股价近期涨跌频繁,不清楚昨日涨停原因。交易双方不存在内幕消息泄露的情形。(21财经)

28分钟前

力箭一号遥六民营商业运载火箭飞行试验任务失利

12月27日9时3分,力箭一号遥六民营商业运载火箭在东风商业航天创新试验区点火升空,火箭飞行异常,飞行试验任务失利。具体原因正在进一步分析排查。(新华社)

28分钟前

韩国央行:超三成韩国人持有加密货币

韩国央行根据在Upbit、Bithumb、Coin One、Cobit和Gopax等五大韩国交易所拥有账户的投资者数量统计发布报告称,截至今年11月,在韩国交易所持有加密货币的人数超过1559万人,比10月份的1498万人增加了61万人。目前,韩国总人口预计在5123万人左右。这意味着,持有加密货币的人口数量相当于总人口的30%以上。报告称,韩国加密货币投资者的数量一直在上升,而在11月更是直线飙升。(财联社)

28分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询